Crisantaspase
drugOn this page
Also known as CrisantaspasaEnrylazeErwinaseJZP-458
Summary
Crisantaspase (CHEMBL2108931) is an approved enzyme; indicated across 7 conditions including acute lymphoblastic leukemia and b-cell acute lymphoblastic leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Enzyme
- Indications: 7 conditions
- Clinical trials: 12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108931 |
| Name | Crisantaspase |
| Type | Enzyme |
| Max phase | 4 |
Also known as: Crisantaspasa, Crisantaspase, Enrylaze, Erwinase, JZP-458, CRISANTASPASE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute lymphoblastic leukemia | 4 | MONDO:0004967 | EFO:0000220 |
| B-cell acute lymphoblastic leukemia | 4 | MONDO:0004947 | EFO:0000094 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| hematopoietic and lymphoid system neoplasm | 2 | MONDO:0002334 | MONDO:0044881 |
| lymphoid leukemia | 2 | MONDO:0005402 | EFO:0004289 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE1 | 3 |
| Not specified | 2 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03643276 | PHASE3 | RECRUITING | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 |
| NCT06336395 | PHASE2 | RECRUITING | Ma-Spore ALL 2020 Study |
| NCT07522801 | PHASE2 | NOT_YET_RECRUITING | A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL |
| NCT00283985 | PHASE2 | COMPLETED | Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma |
| NCT02718755 | PHASE2 | WITHDRAWN | Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies |
| NCT04326439 | PHASE2 | TERMINATED | AflacLL1901 (CHOA-AML) |
| NCT00693602 | PHASE1 | COMPLETED | Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma |
| NCT00928200 | PHASE1 | TERMINATED | Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) |
| NCT02283190 | PHASE1 | COMPLETED | 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) |
| NCT07059975 | EARLY_PHASE1 | RECRUITING | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML |
| NCT00506597 | Not specified | COMPLETED | Erwinase Study in Patients With Acute Lymphoblastic Leukemia |
| NCT04943952 | Not specified | APPROVED_FOR_MARKETING | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).